Trial
NCT01576887
A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis
Phase IIWITHDRAWNSAFETYConfidence: HIGH
Sponsor
Biogen
Collaborators
—
Condition
End-Stage Renal Disease
Intervention
Bardoxolone Methyl 20 mg
Why stopped
IDMC recommendation for safety concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-29